LAUSR

To the Editor: We read with great interest the article by Perri et al. We sincerely appreciate the excellent work of the authors and would like to express some of our opinions. To improve survival and to prevent the delay or absence of adjuvant therapy due to postoperative complications, decreased performance status, and early recurrence, neoadjuvant therapy is encouraged for patients with locally advanced diseases to increase the R0 rate, eliminate micrometastases, and prevent surgery-related treatment delay. Though there is no consensus on the standard application of neoadjuvant therapy in resectable or borderline resectable pancreatic ductal adenocarcinoma, fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is acceptable as neoadjuvant therapy for borderline resectable diseases. The authors generated a new idea of applying postoperative chemotherapy after preoperative therapy and pancreatectomy, which benefited patients with a longer recurrence-free survival time and was marginally associated with a longer overall survival time. In this study, 47% of patients